Peter A McSweeney
Overview
Explore the profile of Peter A McSweeney including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
58
Citations
3754
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Schlatter M, Yandamuri S, OConnor K, Nowak R, Pham M, Obaid A, et al.
Ann Clin Transl Neurol
. 2023 Sep;
10(11):2105-2113.
PMID: 37726935
Objective: Myasthenia gravis (MG) is an autoantibody-mediated neuromuscular junction disorder involving the acetylcholine receptors on the motor endplate. The safety and response to high-dose chemotherapy (HDIT) and autologous hematopoietic cell...
2.
Neelapu S, Jacobson C, Ghobadi A, Miklos D, Lekakis L, Oluwole O, et al.
Blood
. 2023 Feb;
141(19):2307-2315.
PMID: 36821768
In phase 2 of ZUMA-1, a single-arm, multicenter, registrational trial, axicabtagene ciloleucel (axi-cel) autologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapy demonstrated durable responses at 2 years in patients with...
3.
Wang M, Munoz J, Goy A, Locke F, Jacobson C, Hill B, et al.
J Clin Oncol
. 2022 Jun;
41(3):555-567.
PMID: 35658525
Purpose: Brexucabtagene autoleucel (KTE-X19) autologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapy is approved for the treatment of relapsed/refractory mantle cell lymphoma (MCL). Outcomes after a 3-year follow-up in the...
4.
Oluwole O, Bouabdallah K, Munoz J, de Guibert S, Vose J, Bartlett N, et al.
Br J Haematol
. 2021 Jul;
194(4):690-700.
PMID: 34296427
ZUMA-1 (NCT02348216) examined the safety and efficacy of axicabtagene ciloleucel (axi-cel), an autologous CD19-directed chimaeric antigen receptor (CAR)-T cell therapy, in refractory large B-cell lymphoma. To reduce treatment-related toxicity, several...
5.
Wang M, Munoz J, Goy A, Locke F, Jacobson C, Hill B, et al.
N Engl J Med
. 2020 Apr;
382(14):1331-1342.
PMID: 32242358
Background: Patients with relapsed or refractory mantle-cell lymphoma who have disease progression during or after the receipt of Bruton's tyrosine kinase (BTK) inhibitor therapy have a poor prognosis. KTE-X19, an...
6.
Shadman M, Maloney D, Storer B, Sandmaier B, Chauncey T, Andersen N, et al.
Bone Marrow Transplant
. 2019 Sep;
55(1):172-181.
PMID: 31481800
Relapse of chronic lymphocytic leukemia (CLL) after allogeneic hematopoietic cell transplantation (HCT) remains a clinical challenge. We studied in a phase II trial whether the addition of peri-transplant rituximab would...
7.
Locke F, Ghobadi A, Jacobson C, Miklos D, Lekakis L, Oluwole O, et al.
Lancet Oncol
. 2018 Dec;
20(1):31-42.
PMID: 30518502
Background: Axicabtagene ciloleucel is an autologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapy. In the previous analysis of the ZUMA-1 registrational study, with a median follow-up of 15·4 months (IQR...
8.
Maffini E, Storer B, Sandmaier B, Bruno B, Sahebi F, Shizuru J, et al.
Haematologica
. 2018 Sep;
104(2):380-391.
PMID: 30262560
We previously reported initial results in 102 multiple myeloma (MM) patients treated with sequential high-dose melphalan and autologous hematopoietic cell transplantation followed by 200 cGy total body irradiation with or...
9.
Sullivan K, Goldmuntz E, Keyes-Elstein L, McSweeney P, Pinckney A, Welch B, et al.
N Engl J Med
. 2018 Jan;
378(1):35-47.
PMID: 29298160
Background: Despite current therapies, diffuse cutaneous systemic sclerosis (scleroderma) often has a devastating outcome. We compared myeloablative CD34+ selected autologous hematopoietic stem-cell transplantation with immunosuppression by means of 12 monthly...
10.
Storb R, Gyurkocza B, Storer B, Sorror M, Blume K, Niederwieser D, et al.
J Clin Oncol
. 2013 Mar;
31(12):1530-8.
PMID: 23478054
Purpose: We designed a minimal-intensity conditioning regimen for allogeneic hematopoietic cell transplantation (HCT) in patients with advanced hematologic malignancies unable to tolerate high-intensity regimens because of age, serious comorbidities, or...